Bahl & Gaynor Inc Biogen Inc. Transaction History

Bahl & Gaynor Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 13, 2020	SELL	$258.66 - $342.55 $168,646 - $223,342	-652 Closed	0 $0
Q1 2020 May 26, 2020	BUY	$268.85 - $341.04 $175,290 - $222,358	652 New	652 $206,000
Q1 2019 May 13, 2019	SELL	$216.71 - $338.96 $193,522 - $302,691	-893 Closed	0 $0
Q4 2018 Feb 12, 2019	SELL	$278.5 - $352.75 $8,912 - $11,288	-32 Reduced 3.46%	893 $269,000
Q3 2018 Nov 09, 2018	SELL	$293.51 - $383.83 $20,839 - $27,251	-71 Reduced 7.13%	925 $327,000
Q2 2018 Aug 14, 2018	SELL	$257.52 - $306.91 $242,841 - $289,416	-943 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$260.13 - $367.91 $4,682 - $6,622	18 Added 1.95%	943 $258,000
Q4 2017 Feb 13, 2018	SELL	$307.64 - $344.58 $9,844 - $11,026	-32 Reduced 3.34%	925 $295,000
Q3 2017 Nov 13, 2017	SELL	$281.15 - $329.69 $48,076 - $56,376	-171 Reduced 15.16%	957 $300,000
Q2 2017 Aug 11, 2017	BUY	N/A	1,128	1,128 $306,000

998

130M

1.12M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $20.7B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Bahl & Gaynor Inc, based on Form 13F filings with the SEC.

Stay updated on Bahl & Gaynor Inc with notifications on news.